enGene Therapeutics (ENGN) EBIT (2023 - 2026)
enGene Therapeutics (ENGN) posted quarterly EBIT of -$32.0 million for Q2 2026, down 17.86% year-over-year from -$38.9 million in Q2 2025, and down 2.51% quarter-over-quarter from -$31.2 million in Q1 2026.
enGene Therapeutics (ENGN) EBIT (2023 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported EBIT for 4 consecutive years, with -$32.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, EBIT fell 17.86% year-over-year to -$32.0 million; the TTM figure through Apr 2026 stood at -$132.6 million (down 50.74% YoY), while the FY2025 annual figure was -$123.2 million, down 97.71% from the prior year.
- EBIT retreated to -$32.0 million in Q2 2026 per ENGN's latest filing, from -$31.2 million in the prior quarter.
- Across five years, EBIT topped out at -$4.6 million in Q1 2023 and bottomed at -$39.5 million in Q4 2025.
- Historically, EBIT has averaged -$19.6 million across 4 years, with a median of -$17.4 million in 2024.
- Annual changes were most pronounced in 2024 — EBIT plunged 265.42% — and 2026, when it retreated 17.18%.
- enGene Therapeutics' EBIT stood at -$10.4 million in 2023, then tumbled by 67.16% to -$17.5 million in 2024, then slumped by 126.19% to -$39.5 million in 2025, then grew by 19.03% to -$32.0 million in 2026.
- Business Quant data shows ENGN's EBIT at -$32.0 million in Q2 2026, -$31.2 million in Q1 2026, and -$39.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.25 Bn | 131.40 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.31 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.03 Bn | 9.63 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 133.12 Mn |
| 10 | enGene Therapeutics | 123.76 Mn | 123.76 Mn | - | -31.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -31.97 Mn |
| Jan 31, 2026 | -31.19 Mn |
| Oct 31, 2025 | -39.48 Mn |
| Jul 31, 2025 | -29.95 Mn |
| Apr 30, 2025 | -27.12 Mn |
| Jan 31, 2025 | -26.61 Mn |
| Oct 31, 2024 | -17.46 Mn |
| Jul 31, 2024 | -16.76 Mn |
| Apr 30, 2024 | -17.31 Mn |
| Jan 31, 2024 | -10.77 Mn |
| Oct 31, 2023 | -10.44 Mn |
| Jul 31, 2023 | -6.25 Mn |
| Apr 30, 2023 | -4.74 Mn |
| Jan 31, 2023 | -4.63 Mn |